Global Oligonucleotide Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oligonucleotide Therapy Market Research Report 2024
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
According to Mr Accuracy reports’s new survey, global Oligonucleotide Therapy market is projected to reach US$ 4746.7 million in 2034, increasing from US$ 3678.1 million in 2022, with the CAGR of 3.6% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oligonucleotide Therapy market research.
Biogen is the industry's biggest player, with more than 76 percent of 2024 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oligonucleotide Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Alnylam Pharmaceuticals Inc.
Biogen
Dynavax Technologies Corp.
Merck and Co.
Miragen Therapeuutics Inc.
Sarepta Therapeutics Inc.
GlaxoSmithKline
Pfizer
Gilead Sciences
Segment by Type
Antisense Oligonucleotide
Aptamer
Others
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oligonucleotide Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
According to Mr Accuracy reports’s new survey, global Oligonucleotide Therapy market is projected to reach US$ 4746.7 million in 2034, increasing from US$ 3678.1 million in 2022, with the CAGR of 3.6% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oligonucleotide Therapy market research.
Biogen is the industry's biggest player, with more than 76 percent of 2024 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oligonucleotide Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Alnylam Pharmaceuticals Inc.
Biogen
Dynavax Technologies Corp.
Merck and Co.
Miragen Therapeuutics Inc.
Sarepta Therapeutics Inc.
GlaxoSmithKline
Pfizer
Gilead Sciences
Segment by Type
Antisense Oligonucleotide
Aptamer
Others
Segment by Application
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Oligonucleotide Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
